Lactobionic Peel 25%

TherapDerma Clinical Decision System™

Transforming PHA science into a structured professional decision
Professional aesthetic medicine requires far more than identifying an indication and selecting a product.
Two patients may present with loss of radiance, dehydration or uneven texture and yet require different strategies depending on barrier function, sensitivity, medical and treatment history, tolerance and the skin’s capacity to recover.
The TherapDerma Clinical Decision System™ (TCDS™) has been developed as a structured reasoning framework designed to transform information obtained during professional assessment into an individualised strategy.
With Lactobionic Peel 25%, this system is particularly relevant because the product occupies a clearly defined position: a superficial 25% PHA peel, with an approximate pH of 3.5 and pKa of 3.6, positioned for sensitive skin exfoliation, hydration, skin barrier support, antioxidant protection and improvement in the appearance of uneven tone.
The TCDS™ helps the professional decide not only:
“Can this peel be used?”
but also:
“Is this genuinely the peel that best responds to the priorities of this skin?”
________________________________________
STEP 1
PATIENT AND SKIN ASSESSMENT
Context comes before the product
The first stage is to identify the variables that may influence the response to the procedure.
The assessment should consider factors such as:
✔ primary reason for consultation;
✔ patient expectations;
✔ relevant medical and dermatological history;
✔ current medication;
✔ history of aesthetic procedures;
✔ homecare products currently used;
✔ skin sensitivity and reactivity;
✔ hydration level;
✔ condition and integrity of the barrier function;
✔ surface texture;
✔ radiance;
✔ visual uniformity of skin tone;
✔ presence of irritation or lesions;
✔ recent or anticipated sun exposure;
✔ ability to comply with post-procedure recommendations.
With Lactobionic Peel 25%, this assessment is particularly important because correctly selected sensitive skin may represent a suitable profile for the procedure, whereas cutaneous hypersensitivity is listed among the documented contraindications.
The distinction between these two situations cannot be resolved simply by applying the label “sensitive skin”.
It requires professional assessment.
________________________________________
STEP 2
EXCLUSION OF CONTRAINDICATIONS
Before asking what can be achieved, confirm that the procedure can be performed
The product-specific documentation lists the following contraindications:
✔ pregnancy and breastfeeding;
✔ herpes;
✔ warts;
✔ secondary infection;
✔ minor skin lesions or scratches;
✔ skin hypersensitivity;
✔ oncological diseases;
✔ eczema;
✔ psoriasis;
✔ renal insufficiency;
✔ cardiac insufficiency;
✔ hepatic insufficiency;
✔ diabetes.
In addition, the product should not be applied to damaged or peeling skin.
Within the TCDS™, identifying a contraindication does not automatically lead to an attempt to “make the peel gentler”.
It leads to a decision:
POSTPONE
REASSESS
SEEK MEDICAL ASSESSMENT WHEN APPROPRIATE
or
DO NOT PERFORM THE PROCEDURE
________________________________________
STEP 3
IDENTIFYING THE PRIORITY
The skin may present several concerns, but the programme needs a priority
Once contraindications have been excluded, the professional should define which need is most relevant.
In a candidate for Lactobionic Peel 25%, priorities may include:
✔ superficial renewal with high tolerance;
✔ dehydration;
✔ loss of skin comfort;
✔ uneven surface texture;
✔ loss of radiance;
✔ visually uneven skin tone;
✔ superficial signs of photoageing;
✔ reduced Skin Quality;
✔ need for antioxidant support.
The product documentation summarises its profile as:
Sensitive Skin Exfoliation
Hydration Enhancement
Skin Barrier Support
Antioxidant Protection
Uneven Tone Appearance
This step helps avoid a common mistake:
trying to address every concern simultaneously without establishing a priority.
________________________________________
STEP 4
IS LACTOBIONIC PEEL 25% THE RIGHT CHOICE?
This is where true product selection begins.
Lactobionic Peel 25% should be considered when there is alignment between:
THE SKIN’S NEED
and
THE BEHAVIOUR OF THE FORMULATION
PHAs have a larger molecular size and a more gradual interaction with the skin surface, supporting superficial exfoliation with a high-tolerance profile while also providing humectant properties.
Its selection therefore becomes particularly relevant when the professional needs to:
✔ renew without pursuing an aggressive response;
✔ prioritise tolerance;
✔ integrate hydration into the treatment objective;
✔ maintain particular attention to barrier function;
✔ develop a progressive programme.
The correct question is not:
“Is this a good peel?”
It is:
“Is this the right peel for this specific priority?”
________________________________________
DIFFERENTIAL DECISION
Lactobionic Peel 25% or Gluconolactone Peel 25%?
This is precisely the type of decision the TCDS™ is designed to help structure.
Both formulations belong to the PHA family and contain 25% active ingredient, with an approximate pH of 3.5, pKa of 3.6 and superficial depth of action, but their cosmetic positioning differs.
LACTOBIONIC PEEL 25%
May be particularly relevant when the following are prominent:
✔ sensitive skin;
✔ need for skin barrier support;
✔ hydration;
✔ antioxidant protection;
✔ appearance of uneven skin tone.
GLUCONOLACTONE PEEL 25%
The documentation particularly associates it with:
✔ hydration support;
✔ gentle exfoliation;
✔ improved appearance of elasticity;
✔ antioxidant protection;
✔ comfort in acne-prone skin;
✔ dark spot appearance.
The TCDS™ therefore prevents selection based on:
“They are both 25% PHAs, so either one will do.”
and transforms it into:
“Which of these two profiles responds more closely to this patient’s priority?”
________________________________________
STEP 5
DEFINING THE OBJECTIVE
Once Lactobionic Peel 25% has been selected, the intended outcome should be clearly defined.
For example:
OBJECTIVE A
Sensitive Skin Renewal™
OBJECTIVE B
Hydration & Barrier Support™
OBJECTIVE C
Glow & Comfort™
OBJECTIVE D
Even Tone Support™
OBJECTIVE E
Photoaging Defense™
OBJECTIVE F
Skin Quality PHA™
The objective should be specific enough to allow subsequent assessment of progress.
“Improve the skin” is not sufficiently precise.
By contrast:
“Progressively improve hydration, comfort and texture while maintaining good tolerance”
allows specific parameters to be observed and reassessed.
________________________________________
STEP 6
PROCEDURE PERSONALISATION
The product may be the same. The procedure does not have to be.
Personalisation should consider:
✔ treatment area;
✔ treatment extent;
✔ quantity of product;
✔ uniform distribution;
✔ surface preparation;
✔ regional sensitivity;
✔ contact time in accordance with current instructions;
✔ skin response during application;
✔ removal or neutralisation method specifically indicated for the formulation;
✔ post-procedure care;
✔ interval before a potential subsequent session.
The available technical documentation does not support establishing mandatory neutralisation with a specific TherapDerma neutraliser for Lactobionic Peel 25%.
The TCDS™ should therefore state:
REMOVAL / NEUTRALISATION ACCORDING TO THE CURRENT PROFESSIONAL PROTOCOL
rather than automatically transferring the procedure used with other peels.
________________________________________
STEP 7
PROFESSIONAL APPLICATION AND REAL-TIME OBSERVATION
The plan is prepared in advance. The skin provides information during the procedure.
During application, the professional should monitor:
✔ product distribution;
✔ response of each area;
✔ level of comfort;
✔ development of erythema;
✔ burning or irritation;
✔ differences in response between areas;
✔ need for early termination of the procedure.
The specific documentation states that if excessive redness or irritation occurs, the product should be washed off immediately with water and use discontinued.
Therefore:
PLANNED PROTOCOL
must never take priority over
ACTUAL SKIN RESPONSE
________________________________________
STEP 8
RECOVERY AND HOMECARE
Progress continues after the product has been removed
Following the procedure, the strategy should remain consistent with the positioning of the peel.
If Lactobionic Peel 25% has been selected because hydration, comfort and barrier function are priorities, homecare should not contradict that logic through over-exfoliation or unnecessarily irritating products.
The plan may include:
✔ gentle cleansing;
✔ hydration;
✔ skin barrier support;
✔ daily photoprotection;
✔ temporary suspension of potentially irritating products where appropriate;
✔ monitoring for unexpected reactions;
✔ adherence to professional recommendations.
The homecare phase is not separate from the treatment.
It forms part of its continuity.
________________________________________
STEP 9
PROFESSIONAL REASSESSMENT
The next session should never be automatic
Before continuing, the professional should assess:
✔ overall tolerance;
✔ recovery of the skin surface;
✔ condition of the barrier function;
✔ hydration;
✔ comfort;
✔ evolution of texture;
✔ evolution of radiance;
✔ visual evolution of skin tone;
✔ occurrence of any unexpected reaction;
✔ level of homecare adherence;
✔ patient satisfaction.
The information obtained may lead to four principal decisions:
CONTINUE
When progress is appropriate and an indication remains.
ADAPT
When benefit is present but one or more parameters require modification.
CHANGE STRATEGY
When the priority has changed or the response no longer justifies maintaining the same approach.
COMPLETE
When the objectives have been achieved or continuing no longer provides justified benefit.
________________________________________
STEP 10
CONTINUE WITH THE PEEL OR INTEGRATE ANOTHER PROCEDURE?
This is where the TCDS™ connects Lactobionic Peel 25% with the TherapDerma Clinical Ecosystem™.
The documentation includes associations with:
✔ hydrating mesotherapy;
✔ Hyaluronic Acid;
✔ antioxidant vitamins;
✔ LED therapy;
✔ gentle radiofrequency;
✔ anti-ageing programmes;
✔ skin revitalisation strategies.
The decision should answer a new question:
IS THE SKIN SURFACE STILL THE PRIORITY?
If the answer is yes:
→ continuing the PHA programme may be sufficient.
If the answer is no:
→ a complementary intervention addressing the new priority may be considered.
Combination is not the automatic next step.
It is a new decision.
________________________________________
DECISION PATHWAY™
Example: sensitive + dehydrated + dull skin
ASSESSMENT
↓
Correctly selected sensitive skin
Dehydration
Loss of radiance
↓
PRIORITY OBJECTIVE
Hydration + renewal with high tolerance
↓
SELECTION
Lactobionic Peel 25%
↓
REASSESSMENT
Good tolerance
Improved hydration
Radiance still insufficient
↓
NEW DECISION
Continue the PHA programme
or
integrate hydrating mesotherapy / Hyaluronic Acid / LED therapy when indicated
↓
REASSESSMENT
↓
MAINTENANCE
This model demonstrates that a protocol is not a fixed sequence.
It is a chain of decisions.
________________________________________
STEP 11
PROFESSIONAL DOCUMENTATION
A sound decision should be reconstructable afterwards
The professional record may include:
✔ initial assessment;
✔ indication;
✔ contraindications excluded;
✔ priority objective;
✔ rationale for selecting Lactobionic Peel 25%;
✔ product and concentration used;
✔ batch number and expiry date where applicable;
✔ treatment area and extent;
✔ technique used;
✔ contact time in accordance with the protocol;
✔ response observed;
✔ method of removal or neutralisation performed;
✔ aftercare advised;
✔ incidents or adverse responses;
✔ subsequent evolution;
✔ decision made during reassessment.
Documentation does not only record what was done.
It also helps explain:
why it was done.
________________________________________
THERAPDERMA ALGORITHM™
From the skin to the strategy
1. ASSESSMENT
↓
2. EXCLUSION OF CONTRAINDICATIONS
↓
3. IDENTIFICATION OF THE PRIORITY
↓
4. ACID / PEEL SELECTION
↓
5. DEFINITION OF THE OBJECTIVE
↓
6. PROCEDURE PERSONALISATION
↓
7. APPLICATION + OBSERVATION
↓
8. REMOVAL / NEUTRALISATION ACCORDING TO THE SPECIFIC PROTOCOL
↓
9. RECOVERY
↓
10. REASSESSMENT
↓
11. DECISION
Continue
Adapt
Integrate
Change strategy
Complete
↓
12. DOCUMENTATION + MAINTENANCE
This algorithm is a reasoning framework.
Not a universal protocol.
________________________________________
QUICK DECISION MATRIX™
Professional question If the answer is YES
Does the skin require superficial renewal? Consider an appropriate peel
Do sensitivity or dehydration influence the strategy? Consider a PHA in particular
Are barrier function and comfort priorities? Lactobionic Peel 25% may be particularly relevant
Is there hypersensitivity or any documented contraindication? Do not perform the procedure
Is the objective compatible with superficial action? Lactobionic Peel 25% may be considered
Has the skin recovered appropriately? Consider continuity if the indication remains
Has the priority need changed? Reassess the selected tool
Would another procedure contribute a different function? Consider sequential integration
Have the objectives already been achieved? Move to maintenance or complete the programme
________________________________________
BENEFITS OF THE THERAPDERMA CLINICAL DECISION SYSTEM™
Using a structured framework can help to:
✔ reduce automatic product selection;
✔ distinguish sensitive skin from a contraindicated condition;
✔ choose between similar peels with greater rationale;
✔ establish priorities when multiple concerns are present;
✔ justify each stage of the programme;
✔ avoid unnecessary combinations;
✔ adapt treatment according to actual evolution;
✔ improve communication with the patient;
✔ document professional reasoning more effectively;
✔ transform an isolated intervention into a structured programme;
✔ increase consistency and the perceived value of treatment.
________________________________________
FROM PROFESSIONAL REASONING TO PATIENT COMMUNICATION
The TCDS™ also has an important role in communication.
A professional could explain:
“I’m going to use Lactobionic Peel 25% because it is one of our peels for sensitive skin.”
But a higher-value explanation would be:
“I’ve selected this PHA because your skin needs renewal, but it also presents dehydration and sensitivity. In your case, I want to improve texture and radiance while maintaining hydration, barrier function and tolerance as priorities.”
The second explanation communicates:
✔ personalisation;
✔ reasoning;
✔ differentiation;
✔ safety;
✔ consistency;
✔ professional value.
The patient no longer feels that a product has simply been assigned to them.
They understand that:
a decision has been made for their skin.
________________________________________
TCDS™ PHILOSOPHY
Do not begin with the product
The TherapDerma Clinical Decision System™ can be summarised in one principle:
Do not begin by asking:
“What can I do with Lactobionic Peel 25%?”
Begin by asking:
“What does this skin need?”
Then:
which objective should we prioritise?
Then:
which tool best responds to that objective?
And only then:
is Lactobionic Peel 25% the appropriate option?
That order completely changes the logic of treatment.
________________________________________
THERAPDERMA CONCLUSION
The TherapDerma Clinical Decision System™ transforms Lactobionic Peel 25% from a product with specific characteristics into a tool selected for a specific professional reason.
Its profile — 25% PHA, superficial action, progressive interaction, high tolerance, humectant properties, skin barrier support and antioxidant activity — acquires true meaning only when it is related to the characteristics of the skin in front of us.
Within the TherapDerma Clinical Ecosystem™, the TCDS™ organises the entire process:
assess → prioritise → select → personalise → apply → observe → recover → reassess → decide.
This way of working offers an advantage that goes far beyond correctly performing a protocol:
it enables the professional to explain, document and justify why that treatment is appropriate for that patient.
Because at TherapDerma, the decision does not begin with the product.
It begins with the skin.